PALATIN TECHS DL-01 (F:PTN) — Market Cap & Net Worth
Market Cap & Net Worth: PALATIN TECHS DL-01 (PTN)
PALATIN TECHS DL-01 (F:PTN) has a market capitalization of $1.97 Million (€1.68 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #29705 globally and #2604 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PALATIN TECHS DL-01's stock price €3.30 by its total outstanding shares 26005800 (26.01 Million).
PALATIN TECHS DL-01 Market Cap History: 2015 to 2026
PALATIN TECHS DL-01's market capitalization history from 2015 to 2026. Data shows growth from $18.58 Million to $100.33 Million (15.93% CAGR).
PALATIN TECHS DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PALATIN TECHS DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTN by Market Capitalization
Companies near PALATIN TECHS DL-01 in the global market cap rankings as of May 5, 2026.
Key companies related to PALATIN TECHS DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PALATIN TECHS DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, PALATIN TECHS DL-01's market cap moved from $18.58 Million to $ 100.33 Million, with a yearly change of 15.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €100.33 Million | 0.00% |
| 2025 | €100.33 Million | +205.56% |
| 2024 | €32.84 Million | -68.60% |
| 2023 | €104.59 Million | +53.57% |
| 2022 | €68.10 Million | +375.08% |
| 2021 | €14.34 Million | -22.96% |
| 2020 | €18.61 Million | -13.80% |
| 2019 | €21.59 Million | +18.33% |
| 2018 | €18.24 Million | -16.67% |
| 2017 | €21.89 Million | +60.00% |
| 2016 | €13.68 Million | -26.35% |
| 2015 | €18.58 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PALATIN TECHS DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.97 Million USD |
| MoneyControl | $1.97 Million USD |
| MarketWatch | $1.97 Million USD |
| marketcap.company | $1.97 Million USD |
| Reuters | $1.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PALATIN TECHS DL-01
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more